Publications by authors named "V Durbecq"
Article Synopsis
- Currently, there are no validated biomarkers to predict how well patients with breast cancer respond to anthracycline treatments.
- The TOP study focused on estrogen receptor-negative tumors and aimed to determine the predictive value of the TOP2A gene and create a gene expression signature for identifying patients unlikely to benefit from anthracyclines.
- The text also includes details on the gene expression and clinical data from the study while offering R code for accessing the dataset and performing quality control and analysis.
Ductal carcinoma in situ (DCIS) is considered a heterogeneous premalignant condition of the breast with a certain probability for progressing to malignancy. There is no standard of care. The updated Van Nuys Prognostic Index (VNPI) 2003 is a clinical tool in treatment decision making.
View Article and Find Full Text PDFArticle Synopsis
- Validated biomarkers predicting response or resistance to anthracyclines in breast cancer are currently missing, leading to the development of the A-Score in the TOP trial to identify patients who may not benefit from this treatment.
- The TOP trial involved 149 patients with ER-negative tumors treated with epirubicin, and found that TOP2A amplification was significantly associated with better treatment response, resulting in a pathologic complete response (pCR) in 14% of evaluable patients.
- The A-Score, which combines TOP2A and other gene signatures, showed a high negative predictive value, suggesting it could be a valuable tool for determining patient response to anthracycline therapy, pending further validation.
Purpose: Circulating Tumor Cells (CTCs) detection and phenotyping are currently evaluated in Breast Cancer (BC). Tumor cell dissemination has been suggested to occur early in BC progression. To interrogate dissemination in BC, we studied CTCs and HER2 expression on CTCs across the spectrum of BC staging.
View Article and Find Full Text PDFPurpose: Optimal management of breast ductal carcinoma in situ (DCIS) is controversial, and many patients are still overtreated. The local death of myoepithelial cells (MECs) is believed to be a pre-requisite to tumor invasion. We thus hypothesized that loss of CD10 expression, a MEC surface peptidase, would signify basement membrane disruption and confer increased risk of relapse in DCIS.
View Article and Find Full Text PDF